Semaglutide and liraglutide are GLP‑1 receptor agonists. Tirzepatide acts on both GIP and GLP‑1 receptors. These differences matter, but a broader mechanism does not automatically make a medicine suitable for every person.
What to know
Treatment starts at a lower dose and is commonly increased gradually according to the product information.
Digestive adverse effects are common, particularly during dose escalation.
Long-term effectiveness and safety should be reviewed with the prescribing clinician.
What a doctor assesses
A medicine is selected only after an individual medical assessment. BMI is one part of the decision, not the decision itself.
- BMI, waist circumference and weight history
- Related conditions and recent test results
- Current medicines, allergies and contraindications
- Previous treatment, goals and ability to attend follow-up
Safety and responsible access
Prescription weight-management medicines can cause adverse effects and are not suitable for everyone. The exact risks, dose escalation and monitoring differ by product. Read the current package leaflet and contact a doctor or pharmacist if anything is unclear.
Questions about this topic
Is GLP-1 treatment the same as insulin?+
No. GLP‑1 medicines and insulin are different treatments. Never substitute or combine medicines without a clinician’s instructions.
Can I decide from this page whether the treatment is suitable for me?+
No. This page is educational. A licensed doctor must consider your history, other medicines, contraindications and local product information.
Official sources
Sources reviewed 12 August 2026.